Evidence map›Paper›PMID 41951624›Full record

ArticleCell death discovery2026

Proteasome dysfunction underlies HERC2-linked neurodevelopmental disorder with Angelman-like clinical features.

Joan Sala-Gaston, Laura Costa-Sastre, Manel Garcia-Diez, Tania López-Hernández, Juanma Ramírez, Nerea Osinalde, Jose Antonio Valer, Claudia Arnedo-Pac, Bernat Crosas, Emma L Baple and 4 more

Abstract read
In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Joan Sala-Gaston *Department of Physiological Sciences, University of Barcelona, IDIBELL, Barcelona, Spain.ORCID http://orcid.org/0000-0003-1947-7944
Laura Costa-Sastre *Department of Physiological Sciences, University of Barcelona, IDIBELL, Barcelona, Spain.
Manel Garcia-DiezDepartment of Physiological Sciences, University of Barcelona, IDIBELL, Barcelona, Spain.
Tania López-HernándezDepartment of Physiological Sciences, University of Barcelona, IDIBELL, Barcelona, Spain.
Juanma RamírezDepartment of Biochemistry and Molecular Biology, Faculty of Science and Technology, UPV/EHU, Leioa, Spain.
Nerea OsinaldeDepartment of Biochemistry and Molecular Biology, Faculty of Science and Technology, UPV/EHU, Leioa, Spain.
Jose Antonio ValerCambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-1184-9491
Claudia Arnedo-PacMRC Toxicology Unit, University of Cambridge, Cambridge, UK.
Bernat CrosasIBMB‑CSIC, Barcelona, Spain.ORCID http://orcid.org/0000-0002-4303-2198
Emma L BapleUniversity of Exeter Medical Research Centre, Exeter, UK.
Andrew H CrosbyUniversity of Exeter Medical Research Centre, Exeter, UK.
Ugo MayorDepartment of Biochemistry and Molecular Biology, Faculty of Science and Technology, UPV/EHU, Leioa, Spain.
Francesc VenturaDepartment of Physiological Sciences, University of Barcelona, IDIBELL, Barcelona, Spain.ORCID http://orcid.org/0000-0001-9673-9405
Jose Luis RosaDepartment of Physiological Sciences, University of Barcelona, IDIBELL, Barcelona, Spain. joseluisrosa@ub.edu.ORCID http://orcid.org/0000-0002-6161-5688

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biallelic hypomorphic variants in the E3 ubiquitin ligase HERC2 cause a neurodevelopmental disorder clinically resembling Angelman syndrome, characterized by global developmental delay, intellectual disability, autism spectrum features, and movement abnormalities. Defining the target substrates of HERC2 is essential for understanding its biological role and the mechanisms underlying its pathological variants. To this end, we performed a quantitative proteomic analysis using biotinylated ubiquitin to identify HERC2 targets and assess their regulation in cells expressing HERC2 with or without ubiquitin‑ligase activity. This approach revealed extensive sets of subunits from major multimeric complexes, including the proteasome, the tRNA-biosynthesis machinery, microtubule‑associated assemblies, vesicle‑coat complexes, centrosomes, and the Ski and GATOR2 complexes, as substrates of HERC2-dependent ubiquitylation. Among these, the proteasome emerged as the most prominently affected complex. We identified up to eleven proteins required for assembly of the 19S regulatory particle whose ubiquitylation depends on HERC2. Mechanistically, we show that HERC2 recognizes unassembled subunits via chaperone-mediated interactions and targets them for proteasomal degradation. Loss of this mechanism in HERC2‑deficient cells alters proteasomal activity. It is noteworthy that fibroblasts derived from patients carrying the common pathogenic variant c.1781 C > T (p.Pro594Leu) exhibit impaired processing of 19S subunits and an aberrant increase in proteasome activity. Our findings establish a link between HERC2-related neurodevelopmental disorder and impaired proteasome activity, elucidate the molecular mechanisms through which HERC2 regulates proteostasis and how its disruption contributes to human pathology, and underscore potential therapeutic strategies for affected individuals.

Identifiers

PMID41951624
PMCPMC13187139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.